Price
$82.98+24.54%Social Signal Score
Analyst Ratings
12 analystsRevenue
$1.95B-5.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bryan C. Hanson
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 20,584
- Beta
- 0.75
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.81
Financials
Revenue
$1.95B-5.3%Net Income
$-12.00M-103.4%EBITDA
$57.00M-90.3%Free Cash Flow
$99.00M-68.3%EPS (diluted)
$-0.07-103.4%Shares Outstanding (diluted)
170.80M-1.0%Operating Expenses
$994.00MCash & Debt
$451.00MReturn of Capital
$48.00MRevenue by Segment (annual)
$6.35BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.32B | $1.56B | $8.94 |
| 2024 | $8.25B | $479.00M | $2.77 |
| 2023 | $8.20B | $1.35B | $7.79 |
| 2022 | $8.13B | $1.34B | $7.79 |
| 2021 | $8.17B | $1.46B | $8.47 |
| 2020 | $7.28B | $1.14B | $6.60 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SOLV's reported EPS growth of 6.3% a year over 5 years.
- EPS in 5 years
- $12.13
- Implied price
- $109.17
- Return from $86.48
- 4.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $54.28 — -37.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -3.7% | -15.6% | -9.7% | -5.1% | -1.2% | 2.2% |
| 1.3% | -11.2% | -5.1% | -0.2% | 3.9% | 7.5% |
| 6.3% | -6.8% | -0.4% | 4.8% | 9.1% | 12.8% |
| 11.3% | -2.5% | 4.3% | 9.7% | 14.2% | 18.1% |
| 16.3% | 1.9% | 9.0% | 14.6% | 19.3% | 23.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-46.15%Social Signal Score
Mentions (36)
- Newszacks.com·4d ago·Positive
Solventum (SOLV) Boasts Earnings & Price Momentum: Should You Buy? The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
View source ↗ - News (RSS)fool·10d ago·Positive
SOLV Energy (MWH) Q3 2026 Earnings Call Transcript Management sees power demand reshaping its project pipeline ahead.
View source ↗ - News (RSS)investing·10d ago·Neutral
SOLV Energy Q3 2026 slides: record revenue, raised guidance
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Solventum Q3 Earnings Call Highlights Solventum NYSE: SOLV raised its 2026 earnings outlook after reporting third-quarter results that exceeded its expectations for organic growth and earnings, even as the reversal of advance orders weighed on sales.
View source ↗ - Newszacks.com·16d ago·Positive
SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues Decline Solventum beats Q3 earnings estimates despite an ERP-driven revenue decline, raises its 2026 EPS outlook and advances its portfolio transformation.
View source ↗ - News (RSS)seekingalpha·16d ago·Neutral
Solventum signals 2026 EPS of $7.20 to $7.30 as separation passes 90% completion
View source ↗ - News (RSS)seekingalpha·16d ago·Positive
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Neutral
Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
…h toward the high end of +2.5% to +3.0% range Increases full-year adjusted EPS guidance to $7.20 to $7.30 EAGAN, Minn., Nov. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2026.
View source ↗ - Newszacks.com·17d ago·Positive
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
View source ↗ - Newszacks.com·18d ago·Negative
Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key Metrics Besides Wall Street's top-and-bottom-line estimates for Solventum (SOLV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
SOLV Energy Expands High-Voltage Infrastructure Capabilities with Acquisition of ASB Energy Services SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (Nasdaq: MWH) (“SOLV”), a leading provider of infrastructure services to the power industry, today announced it has completed the acquisition of ASB Energy Services (“ASB”), a Texas-based contractor specializing in substation foundations, civil construction, and battery energy storage system (BESS) infrastructure. The acquisition stre…
View source ↗ - Newszacks.com·20d ago·Neutral
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds? Solventum's Q3 results are likely to face ERP-related order reversals and tariff pressures, while MedSurg, Dental and Acera growth may have supported underlying performance.
View source ↗ - Newszacks.com·30d ago·Positive
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
SOLV Energy to Report Third Quarter 2026 Financial Results on November 12, 2026 SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH) plans to report third quarter 2026 results on Thursday, November 12, 2026. Management will present results during a conference call at 8:30 a.m. Eastern time.
View source ↗ - Newsprnewswire.com·34d ago·Negative
…pun fiber matrix technology with an industry-leading negative pressure wound therapy to optimize healing EAGAN, Minn., Oct. 19, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.
View source ↗ - Newsprnewswire.com·38d ago·Neutral
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026 EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.
View source ↗ - Newszacks.com·45d ago·Neutral
Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive? Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·45d ago·Positive
Why Solventum (SOLV) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsseekingalpha.com·65d ago·Negative
Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow alloca…
View source ↗ - Newszacks.com·66d ago·Positive
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
View source ↗ - Newszacks.com·68d ago·Positive
Why Solventum (SOLV) is a Top Stock for the Long-Term Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·79d ago·Neutral
SOLV Energy: PV Enabler Looks A Lot Brighter Here
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
View source ↗ - Newszacks.com·81d ago·Positive
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist? Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
View source ↗ - Newszacks.com·81d ago·Positive
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
View source ↗ - News (RSS)investing·90d ago·Neutral
Solventum Corp stock hits 52-week high at 90.05 USD
View source ↗ - News (RSS)fool·94d ago·Positive
SOLV Energy (MWH) Q2 2026 Earnings Call Transcript $8.9B backlog provides visibility through 2028 as solar and storage demand surges.
View source ↗ - Newszacks.com·97d ago·Positive
Why Solventum (SOLV) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·100d ago·Neutral
SOLV Plans Health Information Systems Business Spinoff to Drive Growth Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
View source ↗ - Newsmarketbeat.com·101d ago·Neutral
SOLV Energy Q2 Earnings Call Highlights SOLV Energy NASDAQ: MWH reported record first-half results for 2026, citing increased new-construction activity, project execution and contributions from prior acquisitions. The company also raised its full-year revenue and adjusted EBITDA outlook while reporting a 44% year-over-year increase in backlog.
View source ↗ - Newsglobenewswire.com·101d ago·Negative
SOLV Energy Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced financial results for the second quarter ended June 30, 2026. Financial Summary (in $ millions except percentages) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenue 951 536 1,628 944 Gross Profit 1 140 113 259 1…
View source ↗ - Newszacks.com·104d ago·Positive
Here's Why Solventum (SOLV) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
Solventum Q2 Earnings Call Highlights Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $1.77 per share
Typical surprise +9.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$1.45 vs $1.34beat
- Wed, Aug 5$2.55 vs $1.90beat
- Tue, May 5$1.48 vs $1.35beat
- Thu, Feb 26$1.57 vs $1.50beat
- Thu, Nov 6$1.50 vs $1.43beat
- Thu, Aug 7$1.69 vs $1.45beat
Estimates and results for SOLV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SOLV officers and directors.
- Bought
- $100k
- Sold
- —
1 trade
0 trades
- Wendell Amy Mcbridebought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- French Hillhouse · AR02 · disclosed Jan 23, 2026 (23d later)Sell$15,001 - $50,000
- Ronald Lee Wydensenate · OR · disclosed Feb 21, 2025 (15d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Feb 12, 2025 (28d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jun 14, 2024 (42d later)Buy$1,001 - $15,000
- Gary C. Peterssenate · MI · disclosed May 23, 2024 (9d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
